Belgium – Healthcare, Regulatory and Reimbursement Landscape

GlobalData, the industry analysis specialist, has released its latest report: “Belgium – Healthcare, Regulatory and Reimbursement Landscape”. The report is an essential source of information on analysis of healthcare, regulatory, and reimbursement landscape in Belgium. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

The Belgium pharmaceutical market was worth $7.90 in 2013, which increased to $8.00B in 2019 at a CAGR of 3.1%. The market value is expected to increase further to $8.10B by 2025. Belgium is a well-developed healthcare market in Western Europe with universal health coverage. Government initiatives such as eHealth 2019–2021 and Artificial Intelligence for Belgium (AI4Belgium) are intended to encourage the adoption of digital health solutions. Belgium's healthcare infrastructure, aging population, innovation-focused R&D investments in pharmaceutical companies, and increased prevalence of chronic diseases are attributed to the growth of the pharmaceutical market.

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Belgium, and includes:

An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers

Profiles and SWOT analyses of the major players in the pharmaceutical market: Pfizer, Novartis, Sanofi, AstraZeneca, and UCB

Profiles and SWOT analyses of the major players in the medical device market: Abbott, Medtronic, Zimmer Biomet, Agfa-Gevaert NV, and IBA

An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in the healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices

Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure

An overview of the opportunities for and challenges to growth in the Belgium healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to:

Develop business strategies by understanding the trends shaping and driving Belgium’s healthcare market

Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact Belgium’s healthcare market in the future

Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights – Facts about the Belgium Healthcare Market

2.3 Key Highlights: Healthcare Startups in Belgium

2.4 Key Events: Belgium Healthcare Timeline, 2015–2021

2.5 Key Events: Belgium Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2019–2020

2.7 Key Events: Top Completed Deals by Value, 2019–2020

2.8 Country Profile, Belgium, 2020

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Belgium

3.5 Pharmaceutical Market – Market Segments

3.6 Major Therapeutic Areas, Belgium

3.7 COVID-19 Epidemiology, Belgium

3.8 COVID-19 Impact and Developments in the Healthcare Market, Belgium

3.9 COVID-19 Clinical Trials Landscape, Belgium

3.10 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Belgium, 2019–2020

6.2 Deal Analysis: Medical Device Market, Belgium, 2019–2020

7. HealthTech Landscape

7.1 HealthTech Landscape, Belgium

7.2 HealthTech Deals Landscape, Belgium

7.3 Adoption of Technology in Healthcare, Belgium

7.4 Key HealthTech Deals, Belgium

7.5 Government-Sponsored Schemes Promoting Startups, Belgium

7.6 Regulatory Scenario Covering Use of Technology in Healthcare, Belgium

7.7 HealthTech Landscape: Benefits and Risks, Belgium

8. Market Access

8.1 Overview of Healthcare System, Belgium

8.2 Reimbursement Process, Belgium

8.3 Overview of Insurance Providers, Belgium

8.4 Healthcare Spending and Medicine Price Index, Belgium

8.5 Pricing Policies, Belgium

8.6 Regulatory Landscape, Belgium

8.6.1 Marketing Authorization for Pharmaceutical Products, EU

8.6.2 Marketing Authorization for Pharmaceutical Products, Belgium

8.6.3 Market Authorization for Medical Devices, Belgium

8.6.4 Exports and Parallel Imports, Belgium

8.6.5 Intellectual Property Rights, Patent, Belgium

8.6.6 Intellectual Property Rights, Trademarks, Belgium

8.6.7 Clinical Trial Regulation Process, Belgium

8.6.8 Pharmaceutical Clinical Trials Landscape, Belgium

8.6.9 Medical Devices Clinical Trials Landscape, Belgium

8.6.10 Pharmaceutical Export and Import, Belgium

8.6.11 Pharmaceutical Advertisement Regulations, Belgium

8.6.12 Pharmacy Regulations, Belgium

8.6.13 Labeling and Packaging Regulations, Belgium

9. Country Healthcare Landscape

9.1 Belgium Healthcare Policy Highlights

9.2 Healthcare Facilities, Belgium

9.3 Healthcare Parameters, Belgium

9.4 Life Expectancy and Immunization Rate, Belgium

9.5 Environmental Health, Belgium

9.6 Healthcare Personnel, Belgium

9.7 Disease Burden, Belgium

9.8 Healthcare Expenditure, Belgium

10 Trade Associations, Belgium

11 Trade Fairs, Belgium

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

List of Tables

Table 1: Reimbursed Biosimilars, Belgium, 2019

Table 2: Pharmaceutical Market, Belgium, Sales of Patented Drug Products by Major Therapeutic Class ($M), 2019

Table 3: COVID-19 Indicators (Number of Cases), Global and Belgium, 2021

Table 4: COVID-19 In Vitro Diagnostics Products, Belgium, 2020–2021

Table 5: Medical Device Market, Belgium, Major Segments ($M), 2020

Table 6: Orthopedic Devices Market, Belgium, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 7: Cardiovascular Devices Market, Belgium, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 8: General Surgery Market, Belgium, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 9: Wound Care Management Market, Belgium, Revenue ($M) and Market Share (%) of Major Companies, 2019

Table 10: In Vitro Diagnostics Market, Belgium, Revenue ($M) and Market Share (%) of Major Companies, 2018

Table 11:Reimbursement Categories, Belgium, 2020

Table 12: Co-payments, Belgium, 2020

Table 13: Requirements for Parallel Import Authorization, Belgium, 2020

Table 14: Provisions for the Advertisement of Medicines (Human Use), Belgium, 2020

Table 15: Pharmacy License Requirements, Belgium, 2020

Table 16: Primary Package Label Information, Belgium, 2020

Table 17: Blister Package Label Information, Belgium, 2020

Table 18: Small Package Label Information, Belgium, 2020

List of Figures

Figure 1: Pharmaceutical Market, Belgium, Revenue ($B), 2013–2020

Figure 2: Medical Device Market, Belgium, Revenue ($B), 2015–2020

Figure 3: Healthcare Startups in Belgium, 2020

Figure 4: Number of Deals (2019–2020)

Figure 5: 2019–2020 Deal Overview by Region

Figure 6: Country Profile, Belgium, 2020

Figure 7: Pharmaceutical Market, Belgium, Revenue ($B), 2013–2019

Figure 8: Pharmaceutical Market, Belgium, Revenue Forecast ($B), 2020–2025

Figure 9: Pharmaceutical Exports ($B), Belgium, 2012–2019

Figure 10: Top Export Partners, Belgium, 2019

Figure 11: Pharmaceutical Imports ($B), Belgium, 2012–2019

Figure 12: Top Import Partners, Belgium, 2019

Figure 13: Pharmaceutical Supply Channel, Belgium, 2020

Figure 14: Generic Drugs Usage (% share by volume), Belgium, 2012–2018

Figure 15: Generic Drugs Usage (% share by value), Belgium, 2012–2018

Figure 16: OTC Market, Belgium, Revenue ($B), 2013–2019

Figure 17: OTC Market by Drug Category, Belgium, Revenue ($M), 2019

Figure 18: Pharmaceutical Market, Belgium, Sales of Patented Drug Products by Major Therapeutic Class, 2019

Figure 19: COVID-19 (Cases), Belgium, 2020–2021

Figure 20: COVID-19 (Deaths), Belgium, 2020–2021

Figure 21: COVID-19 Clinical Trials Count By Trial Status, Belgium, 2020–2021

Figure 22: COVID-19 Clinical Trials Count By Phase, Belgium, 2020–2021

Figure 23: Top Five COVID-19 Clinical Trials Sponsors By Count, Belgium, 2020–2021

Figure 24: Medical Device Market, Belgium, Revenue ($B), 2015–2020

Figure 25: Medical Device Market, Belgium, Revenue Forecast ($B), 2021–2025

Figure 26: Medical Device Market, Belgium, Major Segments (%), 2020

Figure 27: Orthopedic Devices Market, Belgium, Revenue ($M), 2017–2024

Figure 28: Orthopedic Devices Market, Belgium, Market Share of Major Players (%), 2019

Figure 29: Cardiovascular Devices Market, Belgium, Revenue ($M), 2017–2024

Figure 30: Cardiovascular Devices Market, Belgium, Market Share of Major Players (%), 2019

Figure 31: General Surgery Market, Belgium, Revenue ($M), 2017–2024

Figure 32: General Surgery Market, Belgium, Market Share of Major Players (%), 2019

Figure 33: Wound Care Management Market, Belgium, Revenue ($M), 2017–2024

Figure 34: Wound Care Management Market, Belgium, Market Share of Major Players (%), 2019

Figure 35: In Vitro Diagnostics Market, Belgium, Revenue ($M), 2017–2024

Figure 36: In Vitro Diagnostics Market, Belgium, Market Share of Major Players (%), 2018

Figure 37: Diagnostics Market, Belgium, Revenue ($M), 2015–2020

Figure 38: Diagnostics Market, Belgium, Revenue ($M), 2021–2025

Figure 39: Medical Devices Market, Revenue ($B) of Major Companies, Belgium, 2019

Figure 40: Deal Value and Deal Count, Pharmaceutical Market, Belgium, 2019–2020

Figure 41: Deal Value and Deal Count Subtypes, Pharmaceutical Market, Belgium, 2019–2020

Figure 42: Deal Value and Deal Count, Quarterly, Pharmaceutical Market, Belgium, 2019–2020

Figure 43: Top Therapy Areas by Deal Value, Pharmaceutical Market, Belgium, 2019–2020

Figure 44: Top Therapy Areas by Deal Count, Pharmaceutical Market, Belgium, 2019–2020

Figure 45: Mergers and Acquisitions Deals by Quarter, Pharmaceutical Market, Belgium, 2019–2020 (by Value and by Number)

Figure 46: Venture Financing Deals by Quarter, Pharmaceutical Market, Belgium, 2019–2020 (by Value and by Number)

Figure 47: Deal Value and Deal Count, Medical Devices Market, Belgium, 2019–2020

Figure 48: Deal Value and Deal Count, Quarterly, Medical Devices Market, Belgium, 2019–2020

Figure 49: Deal Value and Deal Count Subtypes, Medical Devices Market, Belgium, 2019–2020

Figure 50: Top Equipment Sectors by Deal Value, Medical Devices Market, Belgium, 2019–2020

Figure 51: Top Equipment Sectors by Deal Count, Medical Devices Market, Belgium, 2019–2020

Figure 52: Venture Financing Deals by Equipment Sector, Medical Devices Market, Belgium, 2019–2020 (by value and by number)

Figure 53: Deal Value ($M), HealthTech, Belgium, 2019–2020

Figure 54: Deal Count ($M), HealthTech, Belgium, 2019–2020

Figure 55: HealthTech Ecosystem, 2020

Figure 56: INAMI Administrative Structure, Belgium, 2020

Figure 57: Drug Reimbursement Process, Belgium, 2020

Figure 58: Types of Reimbursement Claims, Belgium, 2020

Figure 59: OOP Expenditure (% of total expenditure on health), Belgium, 2012–2019

Figure 60: Annual Rate of Change (%), Health Price Index, Belgium, 2013–2019

Figure 61: Federal Agency for Medicines and Health Products, Organization Chart, Belgium, 2020

Figure 62: Marketing Authorization for Pharmaceutical Products, EU, 2020

Figure 63: Centralized Procedure, Belgium, 2019

Figure 64: Decentralized Procedure, Belgium, 2019

Figure 65: Mutual Recognition Procedure, Belgium, 2019

Figure 66: Conformity Assessment of Class I Medical Devices, EU, 2020

Figure 67: Conformity Assessment of Class IIa Medical Devices, EU, 2020

Figure 68: Conformity Assessment of Class IIb Medical Devices, EU, 2020

Figure 69: Conformity Assessment of Class III Medical Devices, EU, 2020

Figure 70: European Patent Approval Process, EU, 2020

Figure 71: Unitary Patent Approval Process, EU, 2020

Figure 72: Trademark Approval Process, Belgium, 2020

Figure 73: Clinical Trial Process, Regulation Approval Process Belgium, 2020

Figure 74: Pharmaceutical Clinical Trials Count By Trial Status, Belgium, 2019–2020

Figure 75: Pharmaceutical Clinical Trials Count By Indication, Belgium, 2019–2020

Figure 76: Pharmaceutical Clinical Trials Count By Phase, Belgium, 2019–2020

Figure 77: Top Five Pharmaceutical Clinical Trials Sponsors By Count, Belgium, 2019–2020

Figure 78: Medical Devices Clinical Trials Count by Trial Status, Belgium, 2019–2020

Figure 79: Medical Devices Clinical Trials Count by Indication, Belgium, 2019–2020

Figure 80: Medical Devices Clinical Trials Count by Category, Belgium, 2019–2020

Figure 81: Top Five Medical Devices Clinical Trial Sponsors by Count, Belgium , 2019–2020

Figure 82: Number of Hospitals, Belgium, 2013–2020

Figure 83: Number of Diagnostic Equipment, Belgium, 2015–2020

Figure 84: Number of Hospital Beds (per 1,000 Population), Belgium, 2013–2020

Figure 85: Number of Acute Care Beds (per 1,000 Population), Belgium, 2013–2020

Figure 86: Number of Psychiatric Care Beds (per 1,000 Population), Belgium, 2013–2020

Figure 87: Life Expectancy at Birth (Years), Belgium, 2013–2020

Figure 88: Immunization Rate (%), Belgium, 2012–2019

Figure 89: CO2 Emissions (Million Tons), Belgium, 2013–2020

Figure 90: PM2.5 (µg per m3), Belgium, 2013–2020

Figure 91: Physicians (per 1,000 Population), Belgium, 2013–2020

Figure 92: Dentists (per 1,000 Population), Belgium, 2013–2020

Figure 93: Pharmacists (per 1,000 Population), Belgium, 2013–2020

Figure 94: Nurses (per 1,000 Population), Belgium, 2013–2020

Figure 95: Major Causes of Mortality (per 1,000 population), Belgium, 2016

Figure 96: Major Causes of Male Mortality (per 1,000 population), Belgium, 2016

Figure 97: Major Causes of Female Mortality (Per 1,000 Population), Belgium, 2016

Figure 98: Disability-Adjusted Life Years by Major Disease (Per 1,000 Population), Belgium, 2016

Figure 99: Healthcare Expenditure as Percentage of GDP (%), Belgium, 2013–2020

Figure 100: Public–Private Share (%), Belgium, 2013–2020

Figure 101: Healthcare Expenditure Components by Function (% of Total Health Expenditure), Belgium, 2018

Figure 102: Pharmaceutical Spending ($ Per Capita), Belgium, 2010–2018

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports